Anne Finucane - CVS Health Independent Director
CVS Stock | USD 79.76 0.33 0.42% |
Director
Ms. Anne M. Finucane is Independent Director of Cvs Caremark Corporationration Ms. Finucane was Vice Chairman of Bank of America Corporationrationration, an international financial services company, since July 2015 and is a member of its executive management team. From 2006 through July 2015 Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. During her twentyplus years as a senior leader at Bank of America and its legacy firms, Ms. Finucane has served as senior advisor to four chief executive officers and the Board of Directors since 2011.
Age | 68 |
Tenure | 13 years |
Address | One CVS Drive, Woonsocket, RI, United States, 02895 |
Phone | 401 765 1500 |
Web | https://www.cvshealth.com |
CVS Health Management Efficiency
The company has Return on Asset of 0.0368 % which means that on every $100 spent on assets, it made $0.0368 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1128 %, implying that it generated $0.1128 on every 100 dollars invested. CVS Health's management efficiency ratios could be used to measure how well CVS Health manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CVS Health's Return On Assets are comparatively stable compared to the past year. Return On Equity is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, CVS Health's Asset Turnover is comparatively stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Jeremy Starkweather | Medigus Ltd ADR | 42 | |
Martha Marsh | Edwards Lifesciences Corp | 72 | |
Aviel Shapira | Medigus Ltd ADR | 61 | |
Yuval Yanai | Medigus Ltd ADR | 65 | |
Prattipati Laxminarain | Microbot Medical | 59 | |
Ori Hershkovitz | Medigus Ltd ADR | 39 | |
Steven Loranger | Edwards Lifesciences Corp | 69 | |
Eitan Machover | Medigus Ltd ADR | 55 | |
Oded Yatzkan | Medigus Ltd ADR | 49 | |
Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
William Link | Edwards Lifesciences Corp | 73 | |
Erez Haimovitz | Medigus Ltd ADR | N/A | |
Solomon Mayer | Microbot Medical | 62 | |
Barbara McNeil | Edwards Lifesciences Corp | 74 | |
Martin Madden | Microbot Medical | 57 | |
John Cardis | Edwards Lifesciences Corp | 73 | |
Anat Naschitz | Medigus Ltd ADR | N/A | |
Wesley Schack | Edwards Lifesciences Corp | 74 | |
Scott Burell | Microbot Medical | 52 | |
Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
Yair Rabinovitch | Medigus Ltd ADR | 67 |
Management Performance
Return On Equity | 0.11 | ||||
Return On Asset | 0.0368 |
CVS Health Corp Leadership Team
Elected by the shareholders, the CVS Health's board of directors comprises two types of representatives: CVS Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CVS. The board's role is to monitor CVS Health's management team and ensure that shareholders' interests are well served. CVS Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CVS Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
J Joyner, Executive Vice President | ||
Shawn Guertin, Chief Financial Officer, Executive Vice President | ||
Richard Bracken, Independent Director | ||
Mary Schapiro, Independent Director | ||
Laurence McGrath, Senior Relations | ||
Norman Greve, Chief Officer | ||
David Brown, Independent Director | ||
William Weldon, Independent Director | ||
Kevin Hourican, Executive Vice President, President of CVS Pharmacy | ||
Larry McGrath, Sr Relations | ||
Stephen Gold, Senior Vice President CIO | ||
Joshua Flum, Executive Vice President, Chief Strategy and Business Development Officer | ||
Troyen Brennan, Executive Vice President Chief Medical Officer | ||
Prem Shah, Executive Vice President, Chief Pharmacy Officer and Co-President of Retail | ||
Karen Lynch, President, Chief Executive Officer, Director | ||
Thomas Moriarty, Executive Vice President, General Counsel, Chief Policy and External Affairs Officer | ||
Per Lofberg, Executive Vice President | ||
David Joyner, Executive Vice President | ||
David Falkowski, Executive Officer | ||
Prem PharmD, Chief VP | ||
Jonathan Roberts, Chief Operating Officer, Executive Vice President | ||
Alan Lotvin, Executive Vice President and Presidentident - CVS Caremark | ||
Neela Montgomery, Executive Vice President and President - CVS Pharmacy/Retail | ||
Alan MD, Ex Services | ||
Andrew Sussman, Senior Vice President Associate Chief Medical Officer | ||
Robert Kraft, Executive Vice President | ||
Edward Ludwig, Independent Director | ||
David Dorman, Independent Chairman of the Board | ||
Richard Swift, Independent Director | ||
Fernando Aguirre, Independent Director | ||
Laurie Havanec, Chief People Officer, Executive Vice President | ||
C Brown, Independent Director | ||
NancyAnn DeParle, Independent Director | ||
David CEBS, Executive Caremark | ||
Tilak Mandadi, Data, Digital | ||
Thomas Cowhey, Executive CFO | ||
JeanPierre Millon, Independent Director | ||
Mark Bertolini, Independent Director | ||
Alecia DeCoudreaux, Independent Director | ||
Samrat Esq, Chief VP | ||
Lisa Bisaccia, Chief Human Resource Officer, Executive Vice President | ||
David Denton, CFO and Executive VP | ||
Helena Foulkes, Executive VP and President of CVS Pharmacy Inc | ||
Tony White, Independent Director | ||
Anne Finucane, Independent Director | ||
Vijay Patel, Senior CoFounder | ||
Derica Rice, Executive Vice President, President of CVS Caremark | ||
James Clark, Senior Vice President - Controller, Chief Accounting Officer | ||
Eva Boratto, Chief Financial Officer, Executive Vice President | ||
Daniel Finke, Executive Vice President and Presidentident - Health Care Benefits Segment | ||
Larry Merlo, President, Chief Executive Officer, Director | ||
Roger Farah, Independent Director | ||
Michelle Peluso, Executive Vice President, Chief Customer Officer and Co-President of Retail |
CVS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CVS Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.11 | ||||
Return On Asset | 0.0368 | ||||
Profit Margin | 0.02 % | ||||
Operating Margin | 0.04 % | ||||
Current Valuation | 167.75 B | ||||
Shares Outstanding | 1.26 B | ||||
Shares Owned By Insiders | 0.14 % | ||||
Shares Owned By Institutions | 83.09 % | ||||
Number Of Shares Shorted | 24.17 M | ||||
Price To Earning | 42.99 X |
Pair Trading with CVS Health
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CVS Health position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CVS Health will appreciate offsetting losses from the drop in the long position's value.Moving against CVS Stock
0.43 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
The ability to find closely correlated positions to CVS Health could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CVS Health when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CVS Health - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CVS Health Corp to buy it.
The correlation of CVS Health is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CVS Health moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CVS Health Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CVS Health can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CVS Health Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for CVS Stock analysis
When running CVS Health's price analysis, check to measure CVS Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CVS Health is operating at the current time. Most of CVS Health's value examination focuses on studying past and present price action to predict the probability of CVS Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CVS Health's price. Additionally, you may evaluate how the addition of CVS Health to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is CVS Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CVS Health. If investors know CVS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CVS Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.10) | Dividend Share 2.42 | Earnings Share 6.47 | Revenue Per Share 277.528 | Quarterly Revenue Growth 0.12 |
The market value of CVS Health Corp is measured differently than its book value, which is the value of CVS that is recorded on the company's balance sheet. Investors also form their own opinion of CVS Health's value that differs from its market value or its book value, called intrinsic value, which is CVS Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CVS Health's market value can be influenced by many factors that don't directly affect CVS Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CVS Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if CVS Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CVS Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.